Certain drugs currently used to treat breast, ovarian, and pancreatic cancers could also be used to treat certain gastric cancers with a particular genomic molecular fingerprint.
Researchers identified two new cancer-causing gene mutations that could lead to more targeted and effective treatments for certain lung and prostate cancers.
Genome sequencing database provides easy access to information on clinically important cancer gene mutationsSeptember 25, 2015
Researchers designed an online database, the Cancer Driver Log (CanDL) to help oncologists and other health care professionals identify key mutations that drive tumor growth in tissues.
Scientists have discovered that magnetic resonance imaging (MRI) scanners, normally used to produce images, can be used direct tumor therapies to specific target sites.
Results are in from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated.
New research has identified as few as nine genetic features would need to be tested to identify high-risk patients who might benefit from intensive myeloma treatment.
A new tool predicts what genetics are truly driving the cancer in any population of cells and helps the user choose the best kinase inhibitor to address the issue.
Targeted therapy for skin cancer is effective in patients with sonic hedgehog (SHH) subtype of medulloblastomaAugust 26, 2015
A targeted therapy already used to treat advanced skin cancer has also been found to be effective when used to treat the most common subtype of adult medulloblastoma.
A diet that starves triple-negative breast cancer cells of an essential nutrient primes the cancer cells to be more easily killed by targeted treatment.
New research indicates that treating patients with esophageal cancer with proton therapy produces fewer toxic side effects than utilizing older radiation therapies.
Researchers have reported safely using immune cells grown from patients' own bone marrow to treat multiple myeloma, according to clinical trial data.
Two new targeted treatments slow progression of chronic-lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma.
Researchers have quantified the mutational profiles for cell clusters in individual colorectal cancer tumors that have metastasized.
A new strategy targeting a protein that drives melanoma growth has been proposed in a research report.
Trials results indicate that the pioneering drug olaparib, which targets inherited mutations, can be beneficial for men with prostate cancer.
Accurate administration of proton radiotherapy in mobile organs, such as the lung, can be difficult, but researchers have developed a model that will allow for better beam targeting.
Investigators have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, a discovery that may lead to a new melanoma target or prompt new designs for treatment.
A new triple combination therapy has shown signs that it can more effectively control advanced melanoma that previous, dual-therapy combinations.
A phase 3 trial of brentuximab vedotin (BV) showed that adults with hard-to-treat Hodgkin lymphoma given BV after stem cell transplantation survived without the disease progression for twice as long as when a placebo was administered.
A new online tool uses a patient's molecular characteristics and provides feedback from an expert panel to help oncologists with therapeutic decision-making for advanced non-small cell lung cancer (NSCLC).
Working with cells taken from children with a rare form of brain cancer, scientists have identified a genetic pathway that may spur cancer cell growth and resistance to anticancer treatment.
Researchers have identified a new therapeutic target for a particularly aggressive form of ovarian cancer, opening the door to effective targeted therapy development.
Researchers have developed a device that uses electric fields to drive chemotherapy drugs through the protective barrier of tissue and directly into pancreatic tumors, preventing their growth.
The therapeutic agent SapC-DOPS may have use in lung cancer treatment, according to a new study .
A recent study suggests that targeting a key enzyme and its associated metabolic programming could lead to a novel drug development for lung cancer treatment.
Targeting a specific cell survival protein could be key to treating some lymphomas, including those with genetic defects that make them resistant to standard therapies.
Women with stage 1 HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were unlikely to suffer cancer recurrence within 3 years of treatment.
Researchers believe they may have found a molecule-based approach to halting the destructive quality of the 3q26.2 amplicon, a frequent chromosomal aberrations seen in many cancers, including ovarian and breast cancers.
- Risk of Some Cancers Modestly Increased in Persons Who Had Herpes Zoster
- Targeted Treatment Produces Rapid Shrinkage of Recurrent BRAF-mutant Brain Tumor
- Blood Test Indicates Breast Cancer Tumors Developed Resistance to Hormone Treatment
- Breakthrough Advance Announced in International Blood Cancer Drug Trial
- Gut Bacteria Can Dramatically Amplify Cancer Immunotherapy
- Breastfeeding Associated With A Reduced Risk of Aggressive Breast Cancer
- Hospitals Should Enact Bereavement Programs, Researchers Urge
- Physical Activity Communications Should be Part of Oncology Care Clinic Visits With Patients
- Communication Practices of Many US Physicians May Be Discouraging HPV Vaccination
- Navigation Program Tackles Cancer Care on Two Fronts
- Liquid Biopsy of Cerebrospinal Fluid More Effective in Managing Brain Tumors
- Nivolumab Indications Extended to Include Advanced Renal Cell Carcinoma
- S-1 as First-line Chemo for HER2- Metastatic Breast Cancer
- Nanoliposomal Irinotecan Extends Survival in Metastatic Pancreatic Cancer
- Blood Test Identifies Mutations Behind Drug Resistance in Patients Taking Antiandrogen for Prostate Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|